Future oncology (London, England) · 2021
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fabi Alessandra, Terrenato Irene, Vidiri Antonello, Villani Veronica, Tanzilli Antonio, Airoldi Mario, Pedani Fulvia, Magri Valentina, Palleschi Michela, Donadio Michela, Catania Giovanni, Nisticò Cecilia, Carapella Carmine, Rudà Roberta, Pace Andrea, Maschio Marta, Telera Stefano, Cognetti Francesco, AINO (Associazione Italiana Neuro-Oncologia)
Аннотация
Background: Eribulin shows some activity in controlling brain metastasis in breast cancer. Methods: This observational, multicenter study evaluated brain disease control rates, survival and safety in patients with brain metastatic breast cancer treated with eribulin in clinical practice. Results: A total of 34 patients were enrolled (mean age 49 years, 91% with visceral metastases) and 29 were evaluable for brain disease. Fourteen achieved disease control and showed a longer time without progression: 10 months (95% CI: 2.3-17.7) versus 4 months (95% CI: 3.3-4.7) in the control group (p = 0.029). Patients with clinical benefits at 6 months had longer survival. Leukopenia and neutropenia were the most frequent grade 3-4 toxicities. Conclusion: Eribulin confirms its effectiveness in patients with brain metastatic breast cancer. Further studies on larger cohorts are needed to confirm the results.